Pharmaceuticals
Ascentage Pharma Announces 2021 Interim Results Highlighting the Potential of Its Core Drug Candidates and Major Breakthroughs in Strategic Collaborations
SUZHOU, China, and ROCKVILLE, Md., Aug. 24, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its 2021 interim results and released an updat...
2021-08-24 19:06
2725
Alphamab Oncology and CSPC Achieved an Licensing Cooperation on Anti-HER2 Bispecific Antibody KN026 in Mainland China
SUZHOU, China, Aug. 24, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) announced today that Jiangsu Alphamab Biopharmaceuticals Co., Ltd. ("Jiangsu Alphamab" or "the Company"), a wholly-owned subsidiary of Alphamab Oncology, signed a contract with JMT-Bio, a wholly-owned subsidiary ...
2021-08-24 15:08
2277
China Medical System Holdings Limited 2021 Interim Results Announcement
Business Performance Reached Record High Turnover Increased by 23.6% to RMB3,843.0 Million Profit Increased by 25.5% to RMB1,631.6 Million Industrial Investment Enables Innovation Incubation New Businesses Boost Future Development Financial Highlights For the 6 months ended 30 June 2021 (RMB ...
2021-08-24 10:52
3349
Genscript Biotech Reports 2021 Interim Financial Results
Strong Momentum across All Business Segments, particularly in Gene & Cell Therapy CDMO Continue to accelerate R&D investment to capture Future Growth * Revenue of the Group for the six months ended June 30, 2021 was approximately US$229.6 million, representing an increase of 38.0% as compared...
2021-08-24 01:32
3078
Himalaya Therapeutics Announces Registration of its Office in Shanghai
SHANGHAI and SAN DIEGO, Aug. 23, 2021 /PRNewswire/ -- Himalaya Therapeutics ("Himalaya"), a clinical-stage biopharmaceutical company focused on development and commercialization inGreater China, of a novel class of investigational antibody therapeutics for the treatment of solid tumor cancer, wh...
2021-08-23 22:10
1736
Study Confirms Viraleze Antiviral Nasal Spray Provides Protection Against SARS-CoV-2 in Challenge Model
MELBOURNE, Australia, Aug. 23, 2021 /PRNewswire/ -- Melbourne biotech company Starpharma has announced the publication of new data demonstrating the capability of its Viraleze antiviral nasal spray to protect against SARS-CoV-2 in an animal challenge model of SARS-CoV-2 infection[1]. Viraleze adm...
2021-08-23 20:23
3753
RedHill Biopharma Announces Two New U.S. Patents Covering Opaganib for Ebola Virus and RHB-104 for Crohn's
U.S. patents for opaganib combination for the treatment of Ebola virus disease provides patent protection until 2035 Opaganib's 475-patient global Phase 2/3 study in severe COVID-19 approaching completion with upcoming top-line results Opaganib also undergoing two oncology Phase 2 U.S. studies a...
2021-08-23 19:00
3739
Everest Medicines to Announce Half-Year 2021 Interim Results
SHANGHAI, Aug. 23, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inGreater China and other parts of Asia, today announced t...
2021-08-23 15:20
2957
Menarini Enters into an Exclusive Licensing Agreement with Daiichi Sankyo to Commercialise TARLIGE(R) in Singapore, Malaysia, and the Philippines
SINGAPORE, Aug. 23, 2021 /PRNewswire/ -- A. Menarini Asia-Pacific Holdings Pte. Ltd., part of the leading Italian global biopharmaceutical company Menarini Group, signed a multi-year exclusive licensing agreement to assume the registration, sales, marketing, and distribution of the orally adminis...
2021-08-23 09:00
1818
Inclusion of Kintor as a Constituent Stock of HSCI
SUZHOU, China, Aug. 23, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the company's stock has been included in the Hang Seng Composite ...
2021-08-23 08:44
2554
Ocumension Therapeutics Announces 2021 Interim Results
Company loss narrowed sharply by 96% Business Income Increased By More Than 26 Times Year-on-Year Core Product OT-401 Approval Imminent HONG KONG, Aug. 21, 2021 /PRNewswire/ -- The Chinese ophthalmology platform company,Ocumension Therapeutics ("Ocumension" or the "Company", together with its s...
2021-08-21 00:19
16423
CStone Pharmaceuticals Selected as a Constituent of HSCI
SUZHOU, China, Aug. 20, 2021 /PRNewswire/ -- CStone Pharmaceuticals (HKEX: 2616, "CStone" or the "Company"), a leading biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology therapies and precision medicines, announced that the Company has bee...
2021-08-20 20:24
5272
Standigm Expands Global Footprints with New Office in Cambridge, UK
SEOUL, South Korea, Aug. 20, 2021 /PRNewswire/ -- Standigm, a leading workflow AI drug discovery company, today announced the opening of a new office in Cambridge, United Kingdom ("UK"), to accommodate the company's rapid growth in the European market. Founded in 2015, Standigm has proprietary ...
2021-08-20 15:30
1227
Zhaoke Ophthalmology's Phase III Clinical Trial of Cyclosporine A (CsA) Ophthalmic Gel for Dry Eye Disease Meets Primary Endpoint
Largest Ever Completed Dry Eye Disease (DED) clinical trial to date in China Zhaoke Ophthalmology's in-house developed innovative drug candidate Targeting NDA Filing by the End of 2021 Dry Eye Disease Affects Over 200 Million People in China Potential to become new standard of care for moderate-to-s...
2021-08-19 12:43
3042
MicroConstants to Join BioAgilytix Family
Highly complementary transaction strengthens BioAgilytix's ability to support bioanalytical services across all major therapeutics in development; adds LC/MS/MS capabilities; and expands team of seasoned scientists DURHAM, N.C., Aug. 19, 2021 /PRNewswire/ -- BioAgilytix Labs, LLC (BioAgilytix), ...
2021-08-19 02:30
1569
Seegene Q2 2021 Earnings Show 11 Percent Revenue Growth, YoY
- Revenue of KRW 303.7 billion ($269.1 million) is record for second quarter, up 11 percent year-over-year - 1H'21 Revenue at KRW 655.5 billion ($580.8 million), 58 percent achievement based on total sales in FY2020 - Favorable market conditions expected in second half amid an increasing dem...
2021-08-18 18:00
1461
Transcenta Held Investigator Meeting and Initiated Phase IIa Clinical Trial of Claudin18.2 Monoclonal Antibody TST001 with First Patient Dosed Successfully
SUZHOU, China, Aug. 18, 2021 /PRNewswire/ -- Transcenta announced that it held an investigator meeting successfully for TST001 Phase I clinical trial study on August 14. Professors Lin Shen and Jifang Gong from Beijing Cancer Hospital, ProfessorWeijian Guo from Fudan University Shanghai Cancer Cen...
2021-08-18 08:00
1968
Significant Weight Loss and Multiple Metabolic Benefits: Phase 1b Study Results of IBI362 in Chinese Participants with Overweight or Obesity Published in EClinicalMedicine by the Lancet
SAN FRANCISCO and SUZHOU, China, Aug. 18, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major dise...
2021-08-18 08:00
3568
PT Anugerah Pharmindo Lestari (APL) Won 'Community Initiative' Award and 'Outstanding Leader in Asia' Title for Its President Director at the Asia Corporate Excellence & Sustainability Awards 2021
JAKARTA, Indonesia, Aug. 17, 2021 /PRNewswire/ -- PT Anugerah Pharmindo Lestari (APL), a member of Zuellig Pharma, a leading healthcare services company in Indonesia, has been awarded with the 'Community Initiative' and 'Outstanding Leader inAsia' for APL's President Director, Christophe Piganiol,...
2021-08-17 22:02
2034
Innoforce Pharmaceuticals Opens Analytical Development and Process Development Facility in Hangzhou, China
HANGZHOU, China and ROCKVILLE, Md., Aug. 17, 2021 /PRNewswire/ -- Innoforce Pharmaceuticals ("Innoforce"), a biopharmaceutical innovation and partnership company, today announces that it has opened a new Advanced Cell and Gene Therapy Development Facility inHangzhou, China. Analytical development...
2021-08-17 19:00
1501
Week's Top Stories
Most Reposted
Ultima Markets Recognised as Most Popular Broker 2024 by BrokersView
[Picked up by 318 media titles]
2024-05-15 12:00
Home to half of the world's top 10 trending tourism destinations, Asia Pacific is making a comeback: Mastercard Economics Institute on travel in 2024
[Picked up by 302 media titles]
2024-05-16 15:00
US-BASED PANDUIT ELEVATES MANUFACTURING LANDSCAPE WITH NEW STATE-OF-THE-ART PLANT IN JOHOR BAHRU, MALAYSIA
[Picked up by 274 media titles]
2024-05-16 09:39
Central Embassy, celebrates its 10th anniversary with a world-class immersive presentation--the first of its kind in Thailand--by renowned artist Daniel Arsham
[Picked up by 272 media titles]
2024-05-10 15:20
Where does China's production capacity come from?
[Picked up by 258 media titles]
2024-05-10 12:01Most Read
Huawei Launching the All-Scenario Smart Telecom Power Solutions
2024-05-11 17:52
8752
Central Embassy, celebrates its 10th anniversary with a world-class immersive presentation--the first of its kind in Thailand--by renowned artist Daniel Arsham
2024-05-10 15:20
8117
Where does China's production capacity come from?
2024-05-10 12:01
7954
China Jo-Jo Drugstores Announces $2.74 Million Registered Direct Offering
2024-05-10 21:20
4980